“Ethics are generally not in play here”: The neutralization techniques of “the bad boy of pharma” Martin Shkreli
Abstract In 2015, the American company Turing Pharmaceuticals increased the price of the drug Daraprim by 5,000 percent overnight. Politicians and healthcare representatives accused Turing’s CEO, Martin Shkreli, of having harmed both vulnerable patient groups and the healthcare system. The present a...
Saved in:
Main Author: | Gustav Grut |
---|---|
Format: | Article |
Language: | Danish |
Published: |
De Nordiske Kriminalistforeninger
2019-12-01
|
Series: | Nordisk Tidsskrift for Kriminalvidenskab |
Online Access: | https://tidsskrift.dk/NTfK/article/view/124798 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Leveraging Blockchain and AI for Pharma Supply Chain Efficiency
by: Mohan Venkataraman
Published: (2024-12-01) -
Emerging Trends in Bioavailability and Pharma-Nutraceutical Potential of Whey Bioactives
by: Adhithyan T. Pillai, et al.
Published: (2024-01-01) -
Big Pharma, Big Bucks, and a Big Pile o’ Pigs
Published: (2001-01-01) -
Still Here
by: Kristine Gustavsen Madsø, et al.
Published: (2025-01-01) -
The Ethical and Spiritual Project of Martin Prozesky: Influences and Interests
by: Maniraj Sukdaven
Published: (2018-10-01)